Abstract 1343
Background
Inhibition of vascular endothelial growth factor (VEGF) has shown antiangiogenic effects and immunomodulatory effects through enhancing tumor infiltration of immune cells in advanced renal cell carcinoma (RCC). Combination of checkpoint inhibitors with targeted therapy has synergistic antitumor activities and recent studies have demonstrated survival benefits. Yet, there are notable safety concerns. We conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of treatment-related adverse events (TRAE) and treatment discontinuation due to TRAE.
Methods
PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019 were queried. RCTs utilizing upfront checkpoint inhibitors combination therapy in patients with advanced RCC were incorporated. The primary meta- analytic approach was a random effects model using the Mantel-Haenszel (MH) method. It was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI).
Results
4 phase III RCTs including 3758 patients with advanced RCC were eligible. The study arm used nivolumab+ ipilimumab, pembrolizumab+ axitinib, avelumab+ axitinib or atezolizumab+ bevacizumab while control arm utilized sunitinib. The randomization ratio was 1:1 in all studies. The pooled RR of any-grade TRAE was significant at 0.97 (95% CI: 0.95 –0.99, P = 0.007) and RR of high-grade TRAE was 0.88 (95% CI: 0.72 –1.09, P = 0.24). Treatment discontinuation due to TRAE was reported in 314 (16.84%) vs 200 (10.75%) in control group with RR of 1.43 (95% CI: 0.79 –2.57, P = 0.23). Treatment-related deaths were noted in 20 (1.07%) in study arm vs 13 (0.70%) in control arm. The pooled RR was not significant at 1.57 (95% CI: 0.62 –4.01, P = 0.34).
Conclusions
The risk of developing any-grade TRAE was reduced in upfront checkpoint inhibitors combination arm compared to standard sunitinib group, favoring combination therapy. Moreover, no increase in the risk of treatment related deaths as well treatment discontinuation due to TRAE was noted in the study arm.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kyaw Zin Thein.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4096 - Patient experience and use of an intervention combining nurse-led telephone and technologies for the monitoring of oral cancer medication
Presenter: Marie Ferrua
Session: Poster Display session 3
Resources:
Abstract
6042 - Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy
Presenter: Emma Masters
Session: Poster Display session 3
Resources:
Abstract
3123 - Turkish Cancer Patients’ Preference for Information and Communication Technologies
Presenter: Esra ildes
Session: Poster Display session 3
Resources:
Abstract
6062 - Unmet Needs in Oncology Research related to radiological response evaluation: a multi-center survey in three European countries
Presenter: Sophie Nisse Durgeat
Session: Poster Display session 3
Resources:
Abstract
6109 - A program implementation to facilitate intraoperative brachytherapy between hospitals
Presenter: Marc Garcia Casellas
Session: Poster Display session 3
Resources:
Abstract
1772 - Using Mobile-Based Health Care Applications Outcomes: Mini Systematic Review
Presenter: Aydanur Aydin
Session: Poster Display session 3
Resources:
Abstract
2792 - Evaluation of an education program for cancer patients receiving chemotherapy
Presenter: Iraqi Amina
Session: Poster Display session 3
Resources:
Abstract
3715 - iGestSaúde: Application for self-management of symptoms during chemotherapy treatment
Presenter: Bruno Magalhaes
Session: Poster Display session 3
Resources:
Abstract
3854 - Palliative care requirements of cancer patients and investigation of knowledge and expectations related to palliative care of the patients and their families
Presenter: Ozlem Topkaya
Session: Poster Display session 3
Resources:
Abstract
4997 - Hospice care, what to expect? An exploration of the expectation of future hospice patients
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract